因为剂量很重要:在AML的前线治疗中,Venetoclax的剂量很重要
Dahniel Sastow1, Hannah Levavi1, Nicole Wagner2
1Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
低甲基化剂 (HMA) 加上venetoclax (VEN) 是老年AML患者的标准药物. 较低剂量或计量VEN可能会减少副作用,同时保持有效性.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 患有急性髓性白血病 (AML) 的老年人/不适合的成年人面临着更差的预后和有限的治疗选择.
- 低甲基化剂 (HMA) 与venetoclax (VEN) 结合,在体外对AML细胞表现出协同作用.
- VIALE-A试验确定了HMA + VEN作为该患者组的标准第一线治疗.
研究的目的:
- 评估HMA + VEN在老年/不适合AML患者中修改剂量策略的疗效和安全性.
- 探索替代剂量方案,以减轻与标准VEN治疗相关的骨髓抑制.
- 评估HMA + VEN在年轻/健康患者以及复发/耐药AML环境中的潜力.
主要方法:
- 审查体外研究表明HMA和VEN的协同作用.
- 追溯研究分析,将标准VIALE-A剂量与减少VEN剂量/持续时间进行比较.
- 对低剂量计量学HMA + VEN疗法数据的检查.
主要成果:
- 减少VEN的剂量/持续时间与HMA结合,在回顾性分析中显示了与标准VIALE-A疗法相似的结果.
- 低剂量计量学HMA + VEN证明了临床益处与最小化骨髓毒性.
- 标准的28天VEN周期与显著的骨髓抑制有关,需要剂量调整并导致治疗延迟.
结论:
- 修改HMA + VEN的剂量可能为老年/不适合AML患者提供标准治疗方案的可行替代方案,可能降低毒性.
- 进一步的临床试验至关重要,以确定与HMA结合的最佳VEN剂量.
- 研究HMA + VEN与适合患者的密集疗法以及其在复发/耐药AML中的使用是有必要的.
更多相关视频
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14:51Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
